title: Ongoing clinical trials evaluating the cardiovascular safety and efficacy of therapeutic approaches to diabetes mellitus.
abstract: Research has substantiated that patients with type 2 diabetes mellitus are at increased risk for cardiovascular (CV) disease. It is well established that aggressive management of metabolic risk factors is critical to reducing morbidity and mortality in patients with diabetes. A number of clinical trials are currently focusing on evaluating the safety and efficacy of therapeutic approaches to diabetes. These trials will provide additional information on the role of aggressive management of glucose in patients with diabetes and CV risk. This article provides a summary of these ongoing trials, and discusses the impact of glycemic control and strategies to promote CV risk reduction in patients with diabetes.
authors.affiliation: Section of Endocrinology, Department of Medicine, Tulane University Health Sciences Center, New Orleans, Louisiana 70112, USA. vfonseca@tulane.edu
authors.forename: Vivian A
authors.initials: VA
authors.lastname: Fonseca
mesh_terms: D000218:Adamantane / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D002319:Cardiovascular System / Q000187:drug effects*; D002986:Clinical Trials as Topic; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000503:physiopathology; D004151:Dipeptides / Q000494:pharmacology / Q000627:therapeutic use; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D018450:Disease Progression; D015507:Drugs, Investigational / Q000494:pharmacology; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D006442:Glycated Hemoglobin; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D054795:Incretins / Q000494:pharmacology / Q000627:therapeutic use; D000069450:Liraglutide; D018570:Risk Assessment; D040242:Risk Reduction Behavior
chemical_list: D000218:Adamantane; D004151:Dipeptides; D054873:Dipeptidyl-Peptidase IV Inhibitors; D015507:Drugs, Investigational; D052216:Glucagon-Like Peptide 1; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D054795:Incretins; D000069450:Liraglutide; C502994:saxagliptin